Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663040 | 0.88 | ESR1 (0.55) | ESR1ESR2TRPV1TP53MAPT | |
| SCHEMBL1663398 | 0.80 | TRPV1 (0.72) | ESR1ESR2TRPV1SMN1; SMN2PDE10A | |
| SCHEMBL1664018 | 0.77 | ESR1 (0.49) | ESR1ESR2TRPV1TP53MAPT | |
| SCHEMBL1665818 | 0.77 | SMN1; SMN2 (0.47) | ESR1ESR2TP53MAPTSMN1; SMN2 | |
| SCHEMBL1663858 | 0.76 | TRPV1 (0.55) | ESR1ESR2TRPV1MAPTSMN1; SMN2 | |
| SCHEMBL12605322 | 0.76 | SMN1; SMN2 (0.44) | ESR1ESR2TRPV1SMN1; SMN2PDE10A | |
| SCHEMBL1662878 | 0.75 | ESR2 (0.84) | ESR1ESR2TRPV1KDM4E | |
| SCHEMBL1663337 | 0.74 | NPC1 (0.56) | ESR1ESR2TRPV1TP53MAPT | |
| SCHEMBL10446394 | 0.74 | TRPV1 (0.52) | ESR1ESR2TRPV1SMN1; SMN2KDM4E | |
| SCHEMBL11931941 | 0.73 | TRPV1 (0.52) | ESR1ESR2TRPV1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305652-A2 | Trisubstituted quinazolinone derivatives as vanilloid antagonists | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| EP-1963283-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065662-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | TRPV1, TRPV3, TRPV5 | ESR1 1321/4885ESR2 2159/4885TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.